Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
29 | 108954 | 39.7 | 78% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
7 | 4 | INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY | 1353914 |
29 | 3 | HIV//VIROLOGY//HIV 1 | 108954 |
10 | 2 | AIDS RESEARCH AND HUMAN RETROVIRUSES//VIROLOGY//HIV 1 | 39664 |
61 | 2 | HIV//AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV//ANTIRETROVIRAL THERAPY | 29124 |
571 | 2 | LIPODYSTROPHY//HIV//JOURNAL OF NEUROVIROLOGY | 14362 |
773 | 2 | EFAVIRENZ//NEVIRAPINE//RALTEGRAVIR | 12242 |
1825 | 2 | INTEGRASE//VPR//APOBEC3G | 6199 |
2356 | 2 | NNRTIS//REVERSE TRANSCRIPTASE//HIV DRUG ISTANCE PROGRAM | 4364 |
2828 | 2 | HIV ASSOCIATED NEPHROPATHY//TENOFOVIR//HIVAN | 2999 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | HIV | authKW | 1706764 | 13% | 43% | 14292 |
2 | VIROLOGY | WoSSC | 1124748 | 25% | 16% | 26811 |
3 | HIV 1 | authKW | 1015894 | 5% | 66% | 5522 |
4 | INFECTIOUS DISEASES | WoSSC | 829045 | 26% | 11% | 28609 |
5 | AIDS | journal | 825834 | 5% | 59% | 5054 |
6 | AIDS RESEARCH AND HUMAN RETROVIRUSES | journal | 741826 | 3% | 71% | 3774 |
7 | ANTIRETROVIRAL THERAPY | authKW | 731833 | 3% | 75% | 3514 |
8 | JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | journal | 452288 | 2% | 62% | 2620 |
9 | IMMUNOLOGY | WoSSC | 302708 | 26% | 4% | 28564 |
10 | INFECT DIS | address | 291061 | 8% | 12% | 9111 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Virology | 1124748 | 25% | 16% | 26811 |
2 | Infectious Diseases | 829045 | 26% | 11% | 28609 |
3 | Immunology | 302708 | 26% | 4% | 28564 |
4 | Social Sciences, Biomedical | 58123 | 3% | 7% | 3507 |
5 | Public, Environmental & Occupational Health | 39473 | 9% | 2% | 9853 |
6 | Health Policy & Services | 24405 | 3% | 4% | 2956 |
7 | Microbiology | 24189 | 8% | 2% | 8295 |
8 | Medicine, General & Internal | 11868 | 7% | 1% | 7106 |
9 | Pharmacology & Pharmacy | 7847 | 8% | 1% | 8341 |
10 | Psychology, Multidisciplinary | 5544 | 2% | 1% | 2305 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | AIDS | 356658 | 2% | 51% | 2519 |
2 | INFECT DIS | 291061 | 8% | 12% | 9111 |
3 | HIV DRUG ISTANCE PROGRAM | 90411 | 0% | 75% | 435 |
4 | VIROL | 85805 | 3% | 10% | 3286 |
5 | HIV AIDS PREVENT | 85739 | 1% | 44% | 706 |
6 | RETROVIROL | 80098 | 0% | 58% | 500 |
7 | VACCINE | 59311 | 1% | 30% | 730 |
8 | AARON DIAMOND AIDS | 57795 | 0% | 63% | 329 |
9 | HIV UNIT | 53288 | 0% | 72% | 268 |
10 | BIOSTAT AIDS | 53185 | 0% | 63% | 307 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | AIDS | 825834 | 5% | 59% | 5054 |
2 | AIDS RESEARCH AND HUMAN RETROVIRUSES | 741826 | 3% | 71% | 3774 |
3 | JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 452288 | 2% | 62% | 2620 |
4 | AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 285277 | 2% | 56% | 1851 |
5 | JOURNAL OF VIROLOGY | 246630 | 6% | 15% | 6001 |
6 | AIDS PATIENT CARE AND STDS | 168351 | 1% | 61% | 999 |
7 | HIV MEDICINE | 143003 | 1% | 69% | 750 |
8 | JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 137137 | 1% | 53% | 930 |
9 | ANTIVIRAL THERAPY | 133934 | 1% | 51% | 952 |
10 | RETROVIROLOGY | 116171 | 1% | 59% | 714 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | HIV | 1706764 | 13% | 43% | 14292 | Search HIV | Search HIV |
2 | HIV 1 | 1015894 | 5% | 66% | 5522 | Search HIV+1 | Search HIV+1 |
3 | ANTIRETROVIRAL THERAPY | 731833 | 3% | 75% | 3514 | Search ANTIRETROVIRAL+THERAPY | Search ANTIRETROVIRAL+THERAPY |
4 | AIDS | 547658 | 5% | 40% | 4977 | Search AIDS | Search AIDS |
5 | HIV AIDS | 260466 | 2% | 40% | 2384 | Search HIV+AIDS | Search HIV+AIDS |
6 | HIV INFECTION | 253634 | 2% | 45% | 2052 | Search HIV+INFECTION | Search HIV+INFECTION |
7 | HAART | 205274 | 1% | 61% | 1207 | Search HAART | Search HAART |
8 | HUMAN IMMUNODEFICIENCY VIRUS | 187573 | 2% | 38% | 1794 | Search HUMAN+IMMUNODEFICIENCY+VIRUS | Search HUMAN+IMMUNODEFICIENCY+VIRUS |
9 | ANTIRETROVIRAL | 151371 | 1% | 72% | 755 | Search ANTIRETROVIRAL | Search ANTIRETROVIRAL |
10 | ZIDOVUDINE | 135735 | 1% | 70% | 703 | Search ZIDOVUDINE | Search ZIDOVUDINE |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | LEVY, JA , (1993) PATHOGENESIS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION.MICROBIOLOGICAL REVIEWS. VOL. 57. ISSUE 1. P. 183 -289 | 910 | 77% | 892 |
2 | LI, GD , DE CLERCQ, E , (2016) HIV GENOME-WIDE PROTEIN ASSOCIATIONS: A REVIEW OF 30 YEARS OF RESEARCH.MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS. VOL. 80. ISSUE 3. P. 679 -731 | 532 | 88% | 0 |
3 | CHURCHILL, D , WATERS, L , AHMED, N , ANGUS, B , BOFFITO, M , BOWER, M , DUNN, D , EDWARDS, S , EMERSON, C , FIDLER, S , ET AL (2016) BRITISH HIV ASSOCIATION GUIDELINES FOR THE TREATMENT OF HIV-1-POSITIVE ADULTS WITH ANTIRETROVIRAL THERAPY 2015.HIV MEDICINE. VOL. 17. ISSUE . P. S2 -S104 | 506 | 91% | 0 |
4 | GIRARD, MP , OSMANOV, S , ASSOSSOU, OM , KIENY, MP , (2011) HUMAN IMMUNODEFICIENCY VIRUS (HIV) IMMUNOPATHOGENESIS AND VACCINE DEVELOPMENT: A REVIEW.VACCINE. VOL. 29. ISSUE 37. P. 6191-6218 | 477 | 85% | 60 |
5 | MENENDEZ-ARIAS, L , (2013) MOLECULAR BASIS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 DRUG RESISTANCE: OVERVIEW AND RECENT DEVELOPMENTS.ANTIVIRAL RESEARCH. VOL. 98. ISSUE 1. P. 93-120 | 310 | 95% | 63 |
6 | LEWIS, GK , PAZGIER, M , DEVICO, AL , (2017) SURVIVORS REMORSE: ANTIBODY-MEDIATED PROTECTION AGAINST HIV-1.IMMUNOLOGICAL REVIEWS. VOL. 275. ISSUE 1. P. 271 -284 | 183 | 95% | 2 |
7 | SANDERS, RW , MOORE, JP , (2017) NATIVE-LIKE ENV TRIMERS AS A PLATFORM FOR HIV-1 VACCINE DESIGN.IMMUNOLOGICAL REVIEWS. VOL. 275. ISSUE 1. P. 161 -182 | 177 | 88% | 2 |
8 | DE FEO, CJ , WEISS, CD , (2012) ESCAPE FROM HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) ENTRY INHIBITORS.VIRUSES-BASEL. VOL. 4. ISSUE 12. P. 3859-3911 | 331 | 97% | 10 |
9 | SHAFER, RW , SCHAPIRO, JM , (2008) HIV-1 DRUG RESISTANCE MUTATIONS: AN UPDATED FRAMEWORK FOR THE SECOND DECADE OF HAART.AIDS REVIEWS. VOL. 10. ISSUE 2. P. 67 -84 | 274 | 99% | 166 |
10 | SHAFER, RW , (2002) GENOTYPIC TESTING FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 DRUG RESISTANCE.CLINICAL MICROBIOLOGY REVIEWS. VOL. 15. ISSUE 2. P. 247 -+ | 348 | 99% | 185 |
Classes with closest relation at Level 3 |